Weight management · Phase 2
ZUPREME: petrelintide weight study
What was tested?
Petrelintide versus placebo in adults with obesity or overweight with weight-related conditions. ↗
Registered primary question: Percentage change in body weight at week 28. ↗
What is available so far
This card describes a registered study. No publication results have been appraised for this card. The retrieved registry record does not contain posted results. ↗
Keep in context: The retrieved registry marks the study completed and enrollment as actual, but contains no posted results. A completed registry status alone does not supply an effect estimate. ↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 493 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2026-03-23; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities ↗
Protocol identifier: ZP8396-23094. Sponsor: Zealand Pharma.
Retrieved 2026-09-20; SHA-256 a2d36b0b87f5de73bac31586f05407a69f07b01021771b76fc63cd04020bf763.